{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:23Z","timestamp":1791924443547,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76791-2","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T11:03:03Z","timestamp":1730718183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts"],"prefix":"10.1038","volume":"14","author":[{"given":"Farhana","family":"Jahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annu","family":"Luostarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Hongisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarina","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Vettenranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erja","family":"Kerkel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"76791_CR1","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry, M. Z. et al. A review of treatment options employed in relapsed\/refractory AML. Hematology 28, 2196482 (2023).","journal-title":"Hematology"},{"key":"76791_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0959-8049(00)00058-7","volume":"36","author":"SJ Cotterill","year":"2000","unstructured":"Cotterill, S. J. et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group \u2018Survey\u2019 1982\u20131992. Eur. J. Cancer 36, 901\u2013908 (2000).","journal-title":"Eur. J. Cancer"},{"key":"76791_CR3","doi-asserted-by":"publisher","unstructured":"Krystal, J. & J FosterH Treatment of high-risk neuroblastoma. Children 10. https:\/\/doi.org\/10.3390\/children10081302(2023).","DOI":"10.3390\/children10081302"},{"key":"76791_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood 141, 856\u2013868 (2023).","journal-title":"Blood"},{"key":"76791_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097\u20132100 (2002).","journal-title":"Science"},{"key":"76791_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbmt.2010.02.018","volume":"16","author":"DA Rizzieri","year":"2010","unstructured":"Rizzieri, D. A. et al. Natural killer cell-enriched Donor Lymphocyte infusions from a 3\u20136\/6 HLA matched Family Member following nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 16, 1107\u20131114 (2010).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"76791_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/pbc.25555","volume":"62","author":"JE Rubnitz","year":"2015","unstructured":"Rubnitz, J. E. et al. Natural killer cell therapy in children with relapsed leukemia. Pediatr. Blood Cancer 62, 1468\u20131472 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"76791_CR8","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","volume":"22","author":"A Curti","year":"2016","unstructured":"Curti, A. et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin. Cancer Res. 22, 1914\u20131921 (2016).","journal-title":"Clin. Cancer Res."},{"key":"76791_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen, R. et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J. Immunother Cancer 7, 1\u20137 (2019).","journal-title":"J. Immunother Cancer"},{"key":"76791_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","volume":"18","author":"JR Passweg","year":"2004","unstructured":"Passweg, J. R. et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18, 1835\u20131838 (2004).","journal-title":"Leukemia"},{"key":"76791_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","volume":"48","author":"M Stern","year":"2013","unstructured":"Stern, M. et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transpl. 48, 433\u2013438 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"76791_CR12","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/eji.201444586","volume":"44","author":"M Killig","year":"2014","unstructured":"Killig, M. et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. Eur. J. Immunol. 44, 2822\u20132834 (2014).","journal-title":"Eur. J. Immunol."},{"key":"76791_CR13","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057 (2005).","journal-title":"Blood"},{"key":"76791_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi, J. et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143, 641\u2013653 (2008).","journal-title":"Br. J. Haematol."},{"key":"76791_CR15","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123, 3855\u20133863 (2014).","journal-title":"Blood"},{"key":"76791_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","volume":"22","author":"DA Lee","year":"2016","unstructured":"Lee, D. A. et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. Biol. Blood Marrow Transplant. 22, 1290\u20131298 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"76791_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund, A. T. et al. Complete remission with reduction of high-risk clones following haploidentical NK cell therapy against MDS and AML. Clin. Cancer Res. 24, 1834\u20131844 (2018).","journal-title":"Clin. Cancer Res."},{"key":"76791_CR18","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl Med. 8, 357ra123 (2016).","journal-title":"Sci. Transl Med."},{"key":"76791_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","volume":"37","author":"KH Lee","year":"2023","unstructured":"Lee, K. H. et al. The infusion of ex vivo, interleukin-15 and \u2013\u200921-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients\u2014a randomized trial. Leukemia 37, 807\u2013819 (2023).","journal-title":"Leukemia"},{"key":"76791_CR20","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2016.08.008","volume":"22","author":"I Choi","year":"2016","unstructured":"Choi, I. et al. Donor-derived natural killer cell infusion after human leukocyte antigen\u2013haploidentical hematopoietic cell transplantation in patients with refractory Acute Leukemia. Biol. Blood Marrow Transplant. 22, 2065\u20132076 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"76791_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","volume":"38","author":"S Szmania","year":"2015","unstructured":"Szmania, S. et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J. Immunother. 38, 24\u201336 (2015).","journal-title":"J. Immunother."},{"key":"76791_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea, S. O. et al. Phase 1 clinical trial using mbIL21 ex vivo \u2013 expanded donor-derived NK cells after haploidentical transplantation. Blood 130, 1857\u20131869 (2017).","journal-title":"Blood"},{"key":"76791_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","volume":"177","author":"N Shah","year":"2017","unstructured":"Shah, N. et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br. J. Haematol. 177, 457\u2013466 (2017).","journal-title":"Br. J. Haematol."},{"key":"76791_CR24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger, T. A. et al. A phase 1 trial of CNDO-109\u2013Activated natural killer cells in patients with high-risk Acute myeloid leukemia. Biol. Blood Marrow Transplant. 24, 1581\u20131589 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"76791_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela, M. et al. Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 422, 107\u2013117 (2018).","journal-title":"Cancer Lett."},{"key":"76791_CR26","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.bbmt.2017.07.011","volume":"23","author":"AC Talleur","year":"2017","unstructured":"Talleur, A. C. et al. Consolidation therapy for newly diagnosed pediatric high-risk neuroblastoma patients using busulfan\/melphalan, autologous hematopoietic cell transplant, anti-GD2 antibody, GM-CSF, IL-2 and haploidentical NK cells. Biol. Blood Marrow Transpl. 23, 1910\u20131917 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"76791_CR27","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","volume":"23","author":"SM Federico","year":"2017","unstructured":"Federico, S. M. et al. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma. Clin. Cancer Res. 23, 6441\u20136449 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76791_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000176","volume":"8","author":"R Nguyen","year":"2020","unstructured":"Nguyen, R. et al. Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. J. Immunother Cancer 8, 1\u20138 (2020).","journal-title":"J. Immunother Cancer"},{"key":"76791_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1477461","volume":"7","author":"S Modak","year":"2018","unstructured":"Modak, S. et al. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study. Oncoimmunology 7, 1\u201310 (2018).","journal-title":"Oncoimmunology"},{"key":"76791_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0225998","volume":"14","author":"YB Choi","year":"2019","unstructured":"Choi, Y. B. et al. Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma. PLoS One 14, 1\u201315 (2019).","journal-title":"PLoS One"},{"key":"76791_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453\u2013474 (2010).","journal-title":"Blood"},{"key":"76791_CR32","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/trf.14564","volume":"58","author":"SM Williams","year":"2018","unstructured":"Williams, S. M. et al. Clinical-scale production of cGMP compliant CD3\/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58, 1458\u20131467 (2018).","journal-title":"Transfusion"},{"key":"76791_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/hgtb.2019.039","volume":"30","author":"O Oberschmidt","year":"2019","unstructured":"Oberschmidt, O. et al. Development of automated separation, expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Hum. Gene Ther. Methods 30, 102\u2013120 (2019).","journal-title":"Hum. Gene Ther. Methods"},{"key":"76791_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger, N. et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transpl. 59, 489\u2013495 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"76791_CR35","doi-asserted-by":"publisher","first-page":"1111419","DOI":"10.3389\/fimmu.2023.1111419","volume":"14","author":"R Meazza","year":"2023","unstructured":"Meazza, R. et al. Donor selection for adoptive immunotherapy with NK cells in AML patients: comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Front. Immunol. 14, 1111419 (2023).","journal-title":"Front. Immunol."},{"key":"76791_CR36","doi-asserted-by":"publisher","first-page":"e005577","DOI":"10.1136\/jitc-2022-005577","volume":"10","author":"A Haroun-Izquierdo","year":"2022","unstructured":"Haroun-Izquierdo, A. et al. Adaptive single-KIR\u2009+\u2009NKG2C\u2009+\u2009NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. J. Immunother Cancer 10, e005577 (2022).","journal-title":"J. Immunother Cancer"},{"key":"76791_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2013.00118","volume":"3","author":"U Koehl","year":"2013","unstructured":"Koehl, U. et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front. Oncol. 3, 1\u201312 (2013).","journal-title":"Front. Oncol."},{"key":"76791_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1365-2567.1999.00738.x","volume":"97","author":"F Borrego","year":"1999","unstructured":"Borrego, F., Robertson, M. J., Ritz, J., Pe\u00f1a, J. & Solana, R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 97, 159\u2013165 (1999).","journal-title":"Immunology"},{"key":"76791_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jim.2011.07.016","volume":"372","author":"BV Dons\u2019koi","year":"2011","unstructured":"Dons\u2019koi, B. V., Chernyshov, V. P. & Osypchuk, D. V. Measurement of NK activity in whole blood by the CD69 up-regulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay. J. Immunol. Methods 372, 187\u2013195 (2011).","journal-title":"J. Immunol. Methods"},{"key":"76791_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/0008-8749(85)90219-9","volume":"90","author":"ARE Shaw","year":"1985","unstructured":"Shaw, A. R. E., Bleackley, R. C., Merryweather, J. P. & Barr, P. J. Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell. Immunol. 90, 547\u2013554 (1985).","journal-title":"Cell. Immunol."},{"key":"76791_CR41","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","volume":"180","author":"BWE Carson","year":"1994","unstructured":"Carson, B. W. E. et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395\u20131403 (1994).","journal-title":"J. Exp. Med."},{"key":"76791_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1537-2995.2006.01145.x","volume":"47","author":"DH McKenna","year":"2007","unstructured":"McKenna, D. H. et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47, 520\u2013528 (2007).","journal-title":"Transfusion"},{"key":"76791_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1115178","volume":"5","author":"U Koehl","year":"2016","unstructured":"Koehl, U. et al. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology 5, 1\u201311 (2016).","journal-title":"Oncoimmunology"},{"key":"76791_CR44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1189\/jlb.1008635","volume":"85","author":"C Tomescu","year":"2009","unstructured":"Tomescu, C., Chehimi, J., Maino, V. C. & Montaner, L. J. Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation. J. Leukoc. Biol. 85, 871\u2013876 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"76791_CR45","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager, I. et al. NK cells switch from granzyme B to death receptor\u2013mediated cytotoxicity during serial killing. J. Exp. Med. 216, 2113\u20132127 (2019).","journal-title":"J. Exp. Med."},{"key":"76791_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09033-7","volume":"22","author":"J Liu","year":"2022","unstructured":"Liu, J., Tong, J. & Yang, H. Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer 22, 1\u20137 (2022).","journal-title":"BMC Cancer"},{"key":"76791_CR47","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2018-09-874990","volume":"133","author":"A Hallner","year":"2019","unstructured":"Hallner, A. et al. The HLA-B 221 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood 133, 1479\u20131488 (2019).","journal-title":"Blood"},{"key":"76791_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/CJI.0b013e3181bb46f7","volume":"33","author":"S Huenecke","year":"2010","unstructured":"Huenecke, S. et al. IL-2\u2009\u2013\u2009driven regulation of NK Cell receptors with regard to the distribution of CD16\u2009+\u2009and CD16\u2009\u2013\u2009subpopulations and in vivo influence after haploidentical NK cell infusion. J. Immunother. 33, 200\u2013210 (2010).","journal-title":"J. Immunother."},{"key":"76791_CR49","first-page":"1","volume":"4","author":"European Commission","year":"2017","unstructured":"European Commission. Guidelines on good manufacturing practice specific to advanced therapy medicinal products. Eur. Comm. J. 4, 1\u201332 (2017).","journal-title":"Eur. Comm. J."},{"key":"76791_CR50","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/152581600750062372","volume":"9","author":"BT Bruserud, Gjertsen","year":"2000","unstructured":"Bruserud, Gjertsen, B. T. & Von Volkman, H. L. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J. Hematother. Stem Cell. Res. 9, 923\u2013932 (2000).","journal-title":"J. Hematother. Stem Cell. Res."},{"key":"76791_CR51","unstructured":"Liu, X. & Klein, P. S. Chapter 15. Environmental Catalysis 2185, 389\u2013410 (2020)."},{"key":"76791_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1179\/102453308X315762","volume":"13","author":"A Maha","year":"2008","unstructured":"Maha, A., Cheong, S. K., Leong, C. F. & Seow, H. F. Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome. Hematology 13, 13\u201320 (2008).","journal-title":"Hematology"},{"key":"76791_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0145-2126(88)90076-8","volume":"12","author":"M Salem","year":"1988","unstructured":"Salem, M., Delwel, R., Touw, I., Mahmoud, L. & Lowenberg, B. Human AML colony growth in serum-free culture. Leuk. Res. 12, 157\u2013165 (1988).","journal-title":"Leuk. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76791-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:03:12Z","timestamp":1730991792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76791-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76791"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76791-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.12.593780","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM is an employee of Miltenyi Biotec. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26678"}}